Page 1 - reflections_newsletter

REFLECTIONS

Dyslipidaemia
Dyslipidemia Global Newsletter #1

TABLE OF CONTENTS

KEY ARTICLES On behalf of the Scientific Planning Committee (SPC), I would
2021 ESC Guidelines on cardiovascular disease like to welcome you to the first in a series of newsletters where
prevention in clinical practice. Visseren FLJ, et al. Eur we will summarize the latest clinical and real-world evidence
Heart J. 2021;42(34):3227-3337. in the field of dyslipidemia and reflect on the clinical impact of
Dyslipida
Practical guidance for combination lipid-modifying these data on dyslipidemia management. Every few months we
therapy in high- and very-high-risk patients: A will delve into the recent key articles that may impact clinical
statement from a European Atherosclerosis Society practice. We invite you to interact with this newsletter through
Task Force. Averna M, et al. Atherosclerosis. polling questions, listen/view short clinical perspectives from our
2021;325:99-109. SPC, and click on hyperlinks to the articles for in-depth study.
Efficacy and safety of lowering LDL cholesterol Prof. Farnier (Chair)
in older patients: a systematic review and meta-
analysis of randomised controlled trials. Gencer B, et SCIENTIFIC PLANNING COMMITTEE
al. Lancet. 2020;396(10263):1637-1643.
How low is safe? The frontier of very low (<30 mg/ Prof. Michel Farnier Prof. Augusto Lavalle
dL) LDL cholesterol. Karagiannis AD, et al. Eur Heart J. (France) Cobo
2021;42(22):2154-2169. (Argentina)
New and Emerging Therapies for Reduction of LDL-
Cholesterol and Apolipoprotein B: JACC Focus Prof. Miriam Sandín Prof. Lourdes Santos
Seminar 1/4. Nurmohamed NS, et al. J Am Coll Cardiol. (Spain) (Philippines)
2021;77(12):1564-1575.

Prof. Marcin Welnicki
ADDITIONAL ARTICLES OF INTEREST (Poland)

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.
Visseren FLJ, et al. Eur Heart J. 2021;42(34):3227-3337.

Estimation of cardiovascular disease (CVD) risk, along with
targets for blood lipid levels, are the cornerstone of the guidelines;
however, a new stepwise treatment-intensification approach is also
advocated to achieve these targets, with consideration of CVD risk,
treatment benefit of risk factors, risk modifiers, comorbidities, and
patient preferences.

The new guidelines have replaced the Systemic Coronary Risk
Estimation (SCORE) risk chart with the SCORE2 and SCORE2-
Older Persons (SCORE2-OP) risk charts. In contrast to SCORE,
which provided risk estimates for CVD mortality, SCORE2 provides
risk estimates for the combined outcomes of fatal and non-fatal WATCH
CVD events. Non-high-density lipoprotein cholesterol (non-HDL-C), PROF. VISSEREN REVIEW THE
as opposed to total cholesterol, is used as an input in the SCORE2 UPDATES OF THE 2021 ESC
and SCORE2-OP risk algorithms, which encompass all atherogenic GUIDELINES
(apo-B-containing) lipoprotein measurements. The SCORE2 risk
models are intended for use in people aged 40–69 years, while SCORE2-OP is adjusted for individuals aged over 70.

Learn more at: www.serviercardiomedicalhub.com